Folic acid effect on homocysteine, sortilin levels and glycemic control in type 2 diabetes mellitus patients

Nutr Diabetes. 2022 Jun 22;12(1):33. doi: 10.1038/s41387-022-00210-6.

Abstract

Aim: The present study aimed to determine the folic acid supplement (FAS) effects on serum homocysteine and sortilin levels, glycemic indices, and lipid profile in type II diabetic patients.

Method: A double-blind randomized controlled clinical trial have been performed on 100 patients with T2DM randomly divided into two groups that received either placebo or folic acid 5 mg/d for 12 weeks.

Results: FAS caused a significant decrease in homocysteine and sortilin serum levels (28.2% and 33.7%, P < 0.0001, respectively). After 3 months of intervention, 8.7% decrease in fasting blood glucose (P = 0.0005), 8.2% in HbA1c (P = 0.0002), 13.7% in serum insulin (P < 0.0001) and 21.7% in insulin resistance (P < 0.0001) were found in the folic acid group, however no significant difference was observed in the placebo group. Serum hs-CRP level showed significant positive associations with sortilin (r = 0.237, P = 0.018), homocysteine (r = 0.308, P = 0.002) and fasting blood glucose (r = 0.342, P = 0.000). There were no significant changes in lipid profile in both groups after 12 weeks.

Conclusion: FAS might be beneficial for reducing homocysteine and sortilin levels, enhancing glycemic control, and improved insulin resistance in patients with T2DM.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adaptor Proteins, Vesicular Transport
  • Blood Glucose
  • Diabetes Mellitus, Type 2* / drug therapy
  • Folic Acid / therapeutic use
  • Glycemic Control
  • Homocysteine / therapeutic use
  • Humans
  • Insulin Resistance*
  • Lipids

Substances

  • Adaptor Proteins, Vesicular Transport
  • Blood Glucose
  • Lipids
  • Homocysteine
  • Folic Acid
  • sortilin